Rezera Files for IPO to Advance NLRP3 Inhibitor for Peripheral Artery Disease
By Priya Anand

Rezera Inc., a biotech company focusing on NLRP3 inhibitors, has filed for an initial public offering (IPO) to fund its development of Ruvonoflast, a lead investigational drug for peripheral artery disease (PAD). The company, which rebranded from NodThera earlier this year, aims to leverage public funding to advance its clinical-stage programs.
Ruvonoflast, formerly known as NT-0796, is designed for broad tissue and brain penetration and is set to enter Phase 3 trials targeting PAD in the first half of 2027. This follows the successful completion of the Phase 2 RESOLVE-1 trial, which involved 176 participants and achieved significant reductions in high-sensitivity C-reactive protein, a marker of inflammation.
The company has received regulatory alignment on the core design and endpoints for the upcoming Phase 3 trial. Additionally, Rezera plans to launch the REVEAL-PAD observational study to further understand inflammation in PAD and pre-screen patients for the trial.
Despite the announcement of the IPO filing, there is no accessible SEC document or press release confirming the formal submission, leaving the IPO status unverified from publicly available primary sources.